Scholarlink

<p>The BRAF V600_K601delinsE (c.1799_1801del) mutation is rare, with an estimated prevalence of 0.05% among all tumor types. Therapeutic options for advanced lung adenocarcinoma harboring this mutation are limited. We present a case of a patient with advanced lung adenocarcinoma carrying the BRAF V600_K601delinsE mutation who derived clinical benefit for one year from treatment with dabrafenib plus trametinib. The patient subsequently developed biventricular asynergy and a significant reduction in left ventricular ejection fraction (LVEF). This case of drug-induced cardiomyopathy is presented in the context of this known adverse reaction, which affects nearly 6% of patients receiving this combination regimen. This report contributes experience on the management of this rare genomic subtype and offers perspectives on addressing its associated adverse drug reactions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical efficacy and cardiac toxicity associated with first-line dabrafenib plus trametinib in advanced BRAF V600_K601delinsE-mutated lung adenocarcinoma: a case report and literature review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月10日

查看全文
  • Lu Yang,
  • Xuanjun Liu,
  • Xiang Zhu,
  • Baoshan Cao,
  • Yangchun Gu,
  • Wei Liu

摘要

The BRAF V600_K601delinsE (c.1799_1801del) mutation is rare, with an estimated prevalence of 0.05% among all tumor types. Therapeutic options for advanced lung adenocarcinoma harboring this mutation are limited. We present a case of a patient with advanced lung adenocarcinoma carrying the BRAF V600_K601delinsE mutation who derived clinical benefit for one year from treatment with dabrafenib plus trametinib. The patient subsequently developed biventricular asynergy and a significant reduction in left ventricular ejection fraction (LVEF). This case of drug-induced cardiomyopathy is presented in the context of this known adverse reaction, which affects nearly 6% of patients receiving this combination regimen. This report contributes experience on the management of this rare genomic subtype and offers perspectives on addressing its associated adverse drug reactions.